The draft report “Controversies in the Management of Patients with Type 2 Diabetes” and related voting questions are now posted for public comment. This report will be the subject of deliberation and vote at the next public meeting of CEPAC on Wednesday, October 29, 2014 in Providence, Rhode Island. This report aims to help members of CEPAC and the public understand the latest evidence on the relative effectiveness and value of various treatment options for individuals with type 2 diabetes, including new classes of oral and injectable medications, insulin, and medical devices. The report includes a systematic review of published literature as well as budget impact analyses. It will be available for public comment until Wednesday, October 22, 2014.
Final Actions Guides are now posted to accompany the July 2014 CEPAC report, “Management Options for Patients with Opioid Dependence.” Written as three separate guides for patients, physicians, and policymakers/payers, the Action Guides distill the key recommendations from the report and benchmark best practices related to treatment access and quality. Among the resources included in these guides are sample language and guidance for establishing office-based methadone pilot programs and jail diversion systems, best practice examples for strengthening the coordination of services for patients with opioid dependence, mentorship and training resources for primary care physicians managing patients with substance abuse, and tools to help patients and family members locate treatment providers.Read More
CEPAC has released a final evidence report on management options for patients with opioid dependence. The final report incorporates findings from a recent public meeting of the New England CEPAC, where council members reviewed evidence on the effectiveness and value of different management approaches for opioid dependence and made recommendations to guide practice and policy. The key findings of the review and votes of CEPAC found that treatment programs that use a medication like methadone to replace the opioid (a method known as maintenance therapy) are more effective than short-term managed withdrawal approaches that attempt to discontinue all opioid use (sometimes referred to as detoxification). Short-term withdrawal management programs typically focus on weaning patients off opioids within a 30-day timeframe, while maintenance programs assume patients will remain on medication for longer periods of time.
The final report, titled “Management Options for Patients with Opioid Dependence,” compares common approaches to opioid dependence treatment. It offers insight into which management options provide the best outcomes for patients and how the options compare from a budget impact and cost-effectiveness perspective. The review focuses on three key pharmacologic interventions: methadone, buprenorphine/Suboxone®, and naltrexone.
Read the full press release here.Read More